Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

May 31, 2024 updated by: Asociación para Evitar la Ceguera en México

OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angioid Streaks Treated With a Single Intravitreal Injection of Bevacizumab

Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)

Study Type

Interventional

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Mexico
    • Distrito Federal
      • México city, Distrito Federal, Mexico, 04030
        • Asociación para Evitar la Ceguera en México (APEC)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Clinical diagnosis of Angioid Streaks
  • Choroidal neovascularization associated
  • Untreated patients or patients treated once with PDT

Exclusion Criteria:

  • Ocular surgery excepting uncomplicated phacoemulsification
  • Glaucoma or any other ocular pathology

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
BCVA
Fluoresceine Angiography
Optical Coherence Tomography

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Asociación para Evitar la Ceguera en México

Investigators

  • Principal Investigator: Adriana Solís-Vivanco, MD, Asociación Para Evitar la Ceguera en México
  • Study Chair: Jans Fromow-Guerra, MD PhD, Asociación Para Evitar la Ceguera en México
  • Study Chair: Mariana Martínez-Castellanos, MD, Asociación Para Evitar la Ceguera en México
  • Study Chair: Elizabeth Reyna-Castelán, MD, Asociación Para Evitar la Ceguera en México
  • Study Chair: Myriam Hernández-Rojas, MD, Asociación Para Evitar la Ceguera en México
  • Study Chair: Griselda Alvarez-Rivera, MD, Asociación Para Evitar la Ceguera en México
  • Study Director: Hugo Quiroz-Mercado, MD, Asociación Para Evitar la Ceguera en México

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2005

Primary Completion (Actual)

November 1, 2005

Study Completion (Actual)

May 1, 2006

Study Registration Dates

First Submitted

June 30, 2006

First Submitted That Met QC Criteria

January 23, 2008

First Posted (Estimated)

January 24, 2008

Study Record Updates

Last Update Posted (Actual)

June 3, 2024

Last Update Submitted That Met QC Criteria

May 31, 2024

Last Verified

May 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • APEC 010

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe